Gene Therapy of Anaplastic Thyroid Carcinoma with a Single-Chain Interleukin-12 Fusion Protein

Human Gene Therapy

Volumn 14, Issue 18, 2003, Pages 1741-1751

  Shi, Yufei ^a   Parhar, Ranjit S ^a   Zou, Minjing ^a   Baitei, Essa ^a   Kessie, George ^a   Farid, Nadir R ^b   Alzahrani, Ali ^a   Al Mohanna, Futwan A ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b Osancor Biotech Inc   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HYBRID PROTEIN; INTERLEUKIN 12; NATURAL KILLER CELL ANTIBODY; PROTEIN P35; PROTEIN P40; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CARCINOGENICITY; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXICITY; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNITY; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUDE MOUSE; PROMOTER REGION; SPLEEN CELL; SURVIVAL TIME; THYROID CARCINOMA;

ANIMALIA; CYTOMEGALOVIRUS; MUS MUSCULUS;

EID: 0348147563     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303403322611755     Document Type: Article

References (52)

1. AHMAD, M., and SHI, Y. (2000). TRAIL induced apoptosis of thyroid cancer cells: Potential for therapeutic intervention. Oncogene 19, 3363-3371.
2. ATKINS, M.B., ROBERTSON, M.J., GORDON, M., LOTZE, M.T., DECOSTE, M., DUBOIS, J.S., RITZ, J., SANDLER, A.B., EDIGTON, H.D., GARZONE, P.D., MIER, J.W., CANNING, C.M., BATTIATO, L., TAHARA, H., and SHERMAN, M.L. (1997). Phase 1 evaluation of intravenous recombinant interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3, 409-417.
3. BOGGIO, K., DI CARLO, E., ROVERO, S., CAVALLO, F., QUAGLINO, E., LOLLINI, P-L., NANNI, P., NICOLETTI, G., WOLF, S., MUSIANI, P., and FORNI, G. (2000). Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER-2/neu transgenic mice. Cancer Res. 60, 359-364.
4. BRAIDEN, V., NAGAYAMA, Y., IITAKA, M., NAMBA, H., NIWA, M., and YAMASHITA, S. (1998). Retrovirus-mediated suicide gene/prodrug therapy targeting thyroid carcinoma using a thyroid-specific promoter. Endocrinology 139, 3996-3999.
5. BREYER, B., JIANG, W., CHENG, H., ZHOU, L., PAUL, R., FENG, T., and HE, T.-C. (2001). Adenoviral vector-mediated gene transfer for human gene therapy. Curr. Gene Ther. 1, 149-162.
6. BRUNDA, M.J., LUISTRO, L., WARRIER, R.R., WRIGHT, R.B., HUBBARD, B.R., MURPHY, M., WOLF, S.F., and GATELY, M.K. (1993). Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178, 1223-1230.
7. CAR, B.D., ENG, V.M., LIPMAN, J.M., and ANDERSON, T.D. (1999). The toxicology of interleukin-12, a review. Toxicol. Pathol. 27, 58-63.
8. CAVALLO, F., DI CARLO, E., BUTERA, M., VERRUA, R., COLOMBO, M.P., MUSIANI, P., and FORNI, G. (1999). Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res. 59, 414-421.
9. CHEN, L., CHEN, D., BLOCK, E., O'DONNELL, M., KUFE, D.W., and CLINTON, S.K. (1997). Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J. Immunol. 159, 351-359.
10. COHEN, J. (1995). IL-12 deaths: Explanation and a puzzle. Science 270, 908.
11. COLOMBO, M.P., and TRINCHIERI, G. (2002). Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13, 155-168.
12. COLOMBO, M.P., VAGLIANI, M., SPREAFICO, F., PARENZA, M., CHIODONI, C., MELANI, C., and STOPPACCIARO, A. (1996). Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res. 56, 2531-2534.
13. COUGHLIN, C.M., SALHANY, K.E., GEE, M.S., LA TEMPLE, D.C., KOTENKO, S., MA, X., GRI, G., WYSOCKA, M., KIM, J.E., LIU, L., LIAO, F., FARBER, J.M., PESTKA, S., TRINCHIERI, G., and LEE, W.M. (1998). Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9, 25-34.
14. CUI, J., SHIN, T., KAWANO, T., SATO, H., KONDO, E., TOURA, I., KANEKO, Y., KOSEKI, H., KANNO, M, and TANIGUCHI, M. (1997). Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278, 1623-1626.
15. DEGROOT, L., and ZHANG, R. (2001). Gene therapy for thyroid cancer: Where do we stand? J. Clin. Endocrinol. Metab. 86, 2923-2928.
16. FARID, N.R., SHI, Y., and ZOU, M.J. (1994). Molecular basis of thyroid cancer. Endocr. Rev. 15, 202-232.
17. GILLESSEN, S., CARVAJAL, D., LING, P., PODLASKI, F.J., STREMLO, D.L., FAMILLETTI, P.C., GUBLER, U., PRESKY, D.H., STERN, A.S., and GATELY, M.K. (1995). Mouse interleukin-12 (IL-12) p40 homodimer: A potent IL-12 antagonist. Eur. J. Immunol. 25, 200-206.
18. GOLLOB, J.A., MIER, J.W., VEENSTRA, K., MCDERMOTT, D.F., CLANCY, D., CLANCY, M., and ATKINS, M.B. (2000). Phase 1 trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-γ induction is associated with clinical response. Clin. Cancer Res. 6, 1678-1692.
19. GRI, G., CHIODONI, C., GALLO, E., STOPPACCIARO, A., LIEW, F.Y., and COLOMBO, M.P. (2002). Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-γ: a role for intrinsic tumor immunogenicity and IL-15. Cancer Res. 62, 4390-4397.
20. IWAZAWA, T., CHAU, G-Y., MORI, T., DOOKERAN, K.A., RUBIN, J.T., WATKINS, S., ROBBINS, P.D., LOTZE, M.T., and TAHARA, H. (2001). Potent antitumor effects of intra-arterial injection of fibroblasts genetically engineered to express IL-12 in liver metastasis model of rat: No additional benefit of using retroviral producer cell. Cancer Gene Ther. 8, 17-22.
21. KAWANO, T., CUI, J., KOEZUKA, Y., TOURA, I., KANEKO, Y., SATO, H., KONDO, E., HARADA, M., KOSEKI, H., NAKAYAMA, T., TANAKA, Y., and TANIGUCHI, M. (1998). Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc. Natl. Acad. Sci. U.S.A. 95, 5690-5693.
22. KOBAYASHI, M., FITZ, L., RYAN, M., HEWICK, R.M., CLARK, S.C., CHANG, S., KOUDON, R., SHERMAN, F., PERUSSIA, B., and TRINCHIERI, G. (1989). Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J. Exp. Med. 170, 827-845.
23. LE, H.N., LEE, N.C., TSUNG, K., and NORTON, J.A. (2001). Preexisting tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12. J. Immunol. 167, 6765-6772.
24. LI, D., ZEIDERS, J.W., LIU, S., GUO, M., XU, Y., BISHOP, J.S., and O'MALLEY, B.W. (2001). Combination nonviral cytokine gene therapy for head and neck cancer. Laryngoscope 111, 815-820.
25. LI, S., ZHANG, X., and XIA, X. (2002). Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy. J. Natl. Cancer Inst. 94, 762-768.
26. LODE, H.N., DREIER, T., XIANG, R., VARKI, N.M., KANG, A.S., and REISFELD, R.A. (1998). Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc. Natl. Acad. Sci. U.S.A. 95, 2475-2480.
27. LOTZE, M.T., MATORY, Y.L., ETTINGHAUSEN, S.E., RAYNER, A.A., SHARROW, S.O., SEIPP, C.A.Y., CUSTER, M.C., and ROSENBERG, S.A. (1985). In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J. Immunol. 135, 2865-2875.
28. MCKALLIP, R.J., LOMBARD, C., FISHER, M., MARTIN, B.R., RYU, S., GRANT, S., NAGARKATTI, P.S., and NAGARKATTI, M. (2002). Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100, 627-634.
29. MELERO, I., MAZZOLINI, G., NARVAIZA, I., QIAN, C., CHEN, L., and PRIETO, J. (2001). IL-12 gene therapy for cancer: In synergy with other immunotherapies. Trends Immunol. 22, 113-115.
30. NAGAYAMA, Y., YOKOI, H., TAKEDA, K., HASEGAWA, M., NISHIHARA, E., NAMBA, H., YAMASHITA, S., and NIWA, M. (2000). Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J. Clin. Endocrinol. Metab. 85, 4081-4086.
31. NANNI, P., FORNI, G., and LOLLINI, P.-L. (1999). Cytokine gene therapy: Hopes and pitfalls. Ann. Oncol. 10, 261-266.
32. NASU, Y., BANGMA, C.H., HULL, G.W., LEE, H-M., HU, J., WANG, J., MCCURDY, M.A., SHIMURA, S., YANG, G., TIMME, T.L., and THOMPSON, T.C. (1999). Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther. 6, 338-349.
33. NOGUCHI, Y., JUNGBLUTH, A., RICHARDS, E.C., and OLD, L.J. (1996). Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc. Natl. Acad. Sci. U.S.A. 93, 11798-11801.
34. PARHAR, R.S., SHI, Y., ZOU, M.J., FARID, N.R., ERNST, P., and AL-SEDAIRY, S.T. (1995). Effects of cytokine-mediated modulation of nm23 expression on the invasion and metastatic behavior of B16F10 melanoma cells. Int. J. Cancer 60, 204-210.
35. PARK, S.-H., KYIN, T., BENDELAC, A., and CARNAUD, C. (2003). The contribution of NKT cells, NK cells, and other γ-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. J. Immunol. 170, 1197-1201.
36. PARMIANI, G., RODOLFO, M., and MELANI, C. (2000). Immunological gene therapy with ex vivo gene-modified tumor cells: A critique and a reappraisal. Hum. Gene Ther. 11, 1269-1275.
37. RAKHMILEVICH, A.L., TIMMINS, J.G., JANSSEN, K., POHLMANN, E.L., SHEEHY, M.J., and YANG, N.S. (1999). Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: A direct comparison with systemic IL-12 protein therapy. J. Immunother. 22, 135-144.
38. RODOLFO, M., MELANI, C., ZILOCCHI, C., CAPPETTI, B., LUISON, E., ARIOLI, I., PARENZA, M., CANEVARI, S., and COLOMBO, M.P. (1998). IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases. Cancer Res. 58, 5812-5817.
39. SCHMUTZLER, C., and KOEHRLE, J. (2000). Innovative strategies for the treatment of thyroid cancer. Eur. J. Endocrinol. 143, 15-24.
40. SHI, Y., ZOU, M.J., AHRING, P., AL-SEDAIRY, S.T., and FARID, N.R. (1995). Thyrotropin internalization is directed by a highly conserved motif in the seventh transmembrane region of its receptor. Endocrine 3, 409-414.
41. SHI, Y., PARHAR, R.S., ZOU, M.J., AL-MOHANNA, F.A., and PATERSON, M.C. (2002). Gene therapy of melanoma pulmonary metastasis by intramuscular injection of plasmid DNA encoding tissue inhibitor of metalloproteinases-1. Cancer Gene Ther. 9, 126-132.
42. SMYTH, M.J., TANIGUCHI, M., and STREET, S.E. (2000). The antitumor activity of IL-12: Mechanisms of innate immunity that are model and dose dependent. J. Immunol. 165, 2665-2670.
43. STERN, A.S., PODLASKI, F.J., HULMES, J.D., PAN, Y.C.E., QUINN, P.M., WOLITZKY, A.G., FAMILLETTI, P.C., STREMLO, D.L., TRUITT, T., CHIZZONITE, R., and GATELY, M.K. (1990). Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Natl. Acad. Sci. U.S.A. 87, 6808-6812.
44. STRASLY, M., CAVALLO, F., GEUNA, M., MITOLA, S., COLOMBO, M.P., FORNI, G., and BUSSOLINO, F. (2001). IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J. Immunol. 166, 3890-3899.
45. SUN, Y., JURGOVSKY, K., MOLLER, P., ALIJAGIC, S., DORBIC, T., GEORGIEVA, J., WITTIG, B., and SCHADENDORF, D. (1998). Vaccination with IL-12 gene-modified autologous melanoma cells: Preclinical results and a first clinical phase I study. Gene Ther. 5, 481-490.
46. TAHARA, H., ZITVOGEL, L., STORKUS, W.J., ZEH III, H.J., MCKINNEY, T.G., SCHREIBER, R.D., GUBLER, U., ROBBINS, P.D., and LOTZE, M.T. (1995). Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. 154, 6466-6474.
47. TAKEDA, K., SEKI, S., OGASAWARA, K., ANZAI, R., HASHIMOTO, W., SUGIURA, K., TAKAHASHI, M., SATOH, M., and KUMAGAI, K. (1996). Liver NK1.1+CD4+ αβ T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. J. Immunol. 156, 3366-3373.
48. TRINCHIERI, G. (1996). Interleukin-12, a proinflammatory cytokine with immunomodulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13, 251-276.
49. VOEST, E.E., KENYON, B.M., O'REILLY, M.S., TRUITT, G., D'AMATO, R.J., and FOLKMAN, J. (1995). Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87, 581-586.
50. YAMAZAKI, M., ZHANG, R., STRAUS, F.H., MESSINA, M., ROBINSON, B.C., HASHIZUME, K., and DEGROOT, L.J. (2002). Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12. Gene Ther. 9, 64-74.
51. ZHANG, R., STRAUS, F.H., and DEGROOT, L.J. (2001). An adenoviral vector transducing tissue specific expression of thymidine kinase under the control of thyroglobulin promoter has high specificity and low toxicity in gene therapy. Thyroid 11, 115-123.
52. ZOU, J.P., YAMAMOTO, N., FUJII, T., TAKENAKA, H., KOBAYASHI, M., HERRMANN, S.H., WOLF, S.F., FUJIWARA, H., and HAMAOKA, T. (1995). Systemic administration of rIL-12 induces complete tumor regression and protective immunity: Response is correlated with a striking reversal of suppressed interferon-γ production by antitumor T cells. Int. Immunol. 7, 1135-1145.